Stock listing
NASDAQ:RDHL RedHill Biopharma Ltd. Stock
Follow RedHill Biopharma Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:RDHL
$0.281 USD -0.069 (-19.7%)
Close on Nov 20, 2026
- Day range
- $0.281 – $0.339 USDNov 20, 2026
- Volume
- 24,254 sharesNov 20, 2026
- Market cap
- $2.50M USDAt the close on Nov 20, 2026 · price × 8.89M shares outstanding
- 52-week range
- $0.281 – $1.600 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.72M USDMedian day 89,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RDHL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.281 | -0.069 | -19.7% | $0.311 | $0.339 | $0.281 | 24,254 | |
| $0.350 | 0.000 | 0.0% | $0.350 | $0.350 | $0.330 | 139,147 | |
| $0.350 | -0.011 | -2.9% | $0.360 | $0.375 | $0.350 | 48,643 | |
| $0.361 | -0.015 | -3.9% | $0.375 | $0.385 | $0.361 | 36,685 | |
| $0.375 | -0.006 | -1.6% | $0.370 | $0.393 | $0.370 | 35,193 | |
| $0.381 | +0.015 | +4.1% | $0.370 | $0.400 | $0.360 | 71,197 | |
| $0.366 | -0.009 | -2.4% | $0.384 | $0.387 | $0.366 | 34,250 | |
| $0.375 | -0.020 | -5.0% | $0.395 | $0.400 | $0.375 | 57,678 | |
| $0.395 | -0.033 | -7.7% | $0.430 | $0.440 | $0.391 | 35,024 | |
| $0.428 | +0.002 | +0.4% | $0.420 | $0.450 | $0.420 | 35,363 | |
| $0.426 | +0.004 | +0.9% | $0.440 | $0.450 | $0.420 | 43,111 | |
| $0.422 | +0.006 | +1.5% | $0.395 | $0.422 | $0.395 | 39,097 | |
| $0.416 | -0.026 | -5.8% | $0.440 | $0.456 | $0.410 | 24,168 | |
| $0.442 | +0.054 | +13.8% | $0.390 | $0.471 | $0.390 | 313,494 | |
| $0.388 | -0.029 | -7.0% | $0.400 | $0.410 | $0.380 | 109,100 | |
| $0.417 | -0.011 | -2.6% | $0.438 | $0.438 | $0.390 | 85,000 | |
| $0.428 | -0.020 | -4.5% | $0.445 | $0.449 | $0.422 | 14,400 | |
| $0.448 | +0.032 | +7.7% | $0.410 | $0.449 | $0.408 | 109,300 | |
| $0.416 | -0.007 | -1.7% | $0.415 | $0.441 | $0.390 | 116,200 | |
| $0.423 | +0.001 | +0.2% | $0.410 | $0.447 | $0.410 | 108,100 | |
| $0.422 | -0.033 | -7.3% | $0.465 | $0.468 | $0.414 | 236,600 | |
| $0.455 | -0.052 | -10.3% | $0.470 | $0.490 | $0.455 | 147,200 | |
| $0.507 | +0.006 | +1.2% | $0.483 | $0.520 | $0.460 | 125,200 | |
| $0.501 | +0.021 | +4.4% | $0.496 | $0.515 | $0.486 | 331,600 | |
| $0.480 | -0.019 | -3.8% | $0.500 | $0.520 | $0.480 | 84,900 | |
| $0.499 | +0.013 | +2.7% | $0.487 | $0.515 | $0.483 | 59,400 | |
| $0.486 | -0.029 | -5.6% | $0.505 | $0.510 | $0.480 | 84,700 | |
| $0.515 | -0.018 | -3.4% | $0.515 | $0.533 | $0.500 | 81,600 | |
| $0.533 | -0.006 | -1.1% | $0.543 | $0.560 | $0.513 | 70,000 | |
| $0.539 | -0.039 | -6.7% | $0.545 | $0.592 | $0.520 | 379,300 | |
| $0.578 | +0.104 | +21.9% | $0.499 | $0.691 | $0.435 | 15,754,300 | |
| $0.474 | -0.010 | -2.1% | $0.471 | $0.496 | $0.471 | 36,100 | |
| $0.484 | -0.009 | -1.8% | $0.495 | $0.500 | $0.475 | 57,900 | |
| $0.493 | -0.007 | -1.4% | $0.500 | $0.508 | $0.490 | 90,700 | |
| $0.500 | +0.020 | +4.2% | $0.515 | $0.515 | $0.488 | 130,200 | |
| $0.480 | 0.000 | 0.0% | $0.465 | $0.492 | $0.465 | 556,300 | |
| $0.480 | -0.001 | -0.2% | $0.480 | $0.501 | $0.479 | 217,900 | |
| $0.481 | -0.025 | -4.9% | $0.491 | $0.496 | $0.475 | 92,100 | |
| $0.506 | +0.006 | +1.2% | $0.500 | $0.519 | $0.490 | 89,600 | |
| $0.500 | -0.020 | -3.8% | $0.525 | $0.525 | $0.500 | 102,900 | |
| $0.520 | -0.023 | -4.2% | $0.543 | $0.556 | $0.520 | 89,400 | |
| $0.543 | +0.002 | +0.4% | $0.530 | $0.550 | $0.524 | 80,300 | |
| $0.541 | -0.009 | -1.6% | $0.545 | $0.568 | $0.520 | 200,700 | |
| $0.550 | -0.018 | -3.2% | $0.560 | $0.568 | $0.539 | 77,800 | |
| $0.568 | -0.025 | -4.2% | $0.580 | $0.590 | $0.560 | 81,000 | |
| $0.593 | +0.043 | +7.8% | $0.570 | $0.600 | $0.570 | 230,800 | |
| $0.550 | -0.025 | -4.3% | $0.570 | $0.580 | $0.541 | 217,100 | |
| $0.575 | -0.039 | -6.4% | $0.600 | $0.600 | $0.560 | 252,500 | |
| $0.614 | -0.031 | -4.8% | $0.620 | $0.620 | $0.590 | 207,100 | |
| $0.645 | -0.008 | -1.2% | $0.655 | $0.680 | $0.620 | 265,900 | |
| $0.653 | -0.043 | -6.2% | $0.700 | $0.700 | $0.653 | 152,300 | |
| $0.696 | +0.046 | +7.1% | $0.650 | $0.710 | $0.650 | 224,400 | |
| $0.650 | -0.074 | -10.2% | $0.717 | $0.730 | $0.650 | 400,800 | |
| $0.724 | +0.011 | +1.5% | $0.740 | $0.769 | $0.700 | 575,700 | |
| $0.713 | -0.028 | -3.8% | $0.738 | $0.778 | $0.702 | 445,300 | |
| $0.741 | -0.129 | -14.8% | $0.844 | $0.882 | $0.721 | 1,439,500 | |
| $0.870 | -0.030 | -3.3% | $0.882 | $0.900 | $0.780 | 3,825,600 | |
| $0.900 | +0.239 | +36.2% | $1.360 | $1.600 | $0.900 | 104,018,900 | |
| $0.661 | +0.031 | +4.9% | $0.635 | $0.700 | $0.620 | 42,400 | |
| $0.630 | +0.015 | +2.4% | $0.595 | $0.630 | $0.593 | 35,600 | |
| $0.615 | +0.010 | +1.6% | $0.605 | $0.628 | $0.605 | 16,500 | |
| $0.605 | 0.000 | 0.0% | $0.614 | $0.614 | $0.600 | 4,997 | |
| $0.605 | -0.025 | -3.9% | $0.638 | $0.638 | $0.602 | 11,940 | |
| $0.630 | +0.005 | +0.8% | $0.612 | $0.650 | $0.600 | 19,400 | |
| $0.625 | -0.003 | -0.5% | $0.620 | $0.650 | $0.620 | 15,300 |
Splits
2 splits since 2023 · NASDAQ:RDHL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-40 | Consolidation |
- Ticker
- NASDAQ:RDHL
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor “What This Means” Segment
Nov 17, 2026
Closed $0.35 (-2.9%) on Nov 17, 2026
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
Nov 2, 2026
Closed $0.442 (+13.8%) on Nov 2, 2026
$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
Oct 19, 2026
Closed $0.501 (+4.4%) on Oct 19, 2026
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
Dec 1, 2025
Closed $1.24 (+3.3%) on Dec 1, 2025
RedHill Biopharma Ltd. on 6ix
- News releases
- 5 in the last 12 months · 5 in all · newest Nov 17, 2026 · oldest 2025
- Calls
- 5 calls with a replay · 5 with a transcript · latest Jun 23, 2022
- Decks
- 13 decks · latest Dec 15, 2022
Valuation
price Nov 20, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.88
Team and board
Officers
| Officer | Role |
|---|---|
| Abe Schwartz | President and CEO of Schwartz Technologies Corporation |
| Dror Ben-Asher | Chairman & CEO |
| Razi Ingber | CFO |
| Rick D. Scruggs | President, RedHill Biopharma Inc. & Chief Commercial Officer |
| Gilead Raday | Chief Operating Officer |
| Patricia Anderson | Senior VP Regulatory Affairs |
| Reza Fathi | Senior VP R&D |
| Adi Frish | Chief Corporate & Business Development Officer |
| Guy Goldberg | Chief Business Officer |
| Ira Kalfus | Chief Medical Officer |
| Mark L. Levitt | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Dror Ben-Asher | Chairman & CEO |
| Kenneth Reed | Director |
| Ofer Tsimchi | Director |
| Roni Mamluk | Director |
| Shmuel Cabilly | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| RedHill Biopharma (NASDAQ:RDHL) Q1 2022 Earnings Call | Thu, Jun 23, 2022 · 8:30 AM ET | Replay |
| RedHill Biopharma (NASDAQ:RDHL) Q4 2021 Earnings Call | Thu, Mar 17, 2022 · 8:30 AM ET | Replay |
| RedHill Biopharma (NASDAQ:RDHL) Q3 2021 Earnings Call | Tue, Nov 30, 2021 · 8:30 AM ET | Replay |
| RedHill Biopharma (NASDAQ:RDHL) Q2 2021 Earnings Call | Thu, Aug 26, 2021 · 8:30 AM ET | Replay |
| RedHill Biopharma (NASDAQ:RDHL) Q1 2021 Earnings Call | Thu, May 27, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Mar 12, 2026 | −1.0% |
| Quarter to Sep 30, 2025 | Dec 2, 2025 | −5.7% |
| Quarter to Jun 30, 2025 | Sep 5, 2025 | +17.1% |
| Quarter to Mar 31, 2025 | Apr 10, 2025 | −10.7% |
| Quarter to Dec 31, 2024 | Mar 31, 2025 | −8.6% |
| Quarter to Sep 30, 2024 | Nov 29, 2024 | +2.9% |
| Quarter to Jun 30, 2024 | Aug 29, 2024 · Before open | +3.1% |
| Quarter to Mar 31, 2024 | Apr 8, 2024 · Before open | −0.9% |
| Quarter to Dec 31, 2023 | Feb 12, 2024 · Before open | −2.5% |
| Quarter to Sep 30, 2023 | Nov 15, 2023 | −0.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Jun 30, 2023 | Aug 17, 2023 · Before open | +13.4% |
| Quarter to Mar 31, 2023 | Apr 28, 2023 · Before open | +6.6% |
| Quarter to Dec 31, 2022 | Mar 27, 2023 | −0.6% |
| Quarter to Sep 30, 2022 | Nov 29, 2022 · Before open | −6.1% |
| Q2 2022 | Sep 23, 2022 · After close | +1.4% |
| Quarter to Mar 31, 2022 | Jun 23, 2022 · Before open | +0.2% |
| Quarter to Dec 31, 2021 | Mar 17, 2022 · Before open | +24.6% |
| Quarter to Sep 30, 2021 | Nov 30, 2021 · Before open | +4.3% |
| Q2 2021 | Aug 26, 2021 · Before open | +1.5% |
| Quarter to Mar 31, 2021 | May 27, 2021 · Before open | +1.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2022) | Investor deck | 81 slides | Dec 15, 2022 |
| Investor Presentation (October 2022) | Investor deck | 77 slides | October 2022 |
| Investor Presentation (June 2022) | Investor deck | 77 slides | June 2022 |
| Investor Presentation (April 2022) | Investor deck | 77 slides | Apr 14, 2022 |
| Q3 2021 Earnings Presentation | Earnings | 46 slides | Nov 30, 2021 |
| Technical Presentation (October 2021) | Technical | 25 slides | Oct 7, 2021 |
| Investor Presentation (September 2021) | Investor deck | 71 slides | September 2021 |
| IPO Roadshow (March 2021) | IPO roadshow | 35 slides | Mar 1, 2021 |
| IPO Roadshow (January 2021) | IPO roadshow | 34 slides | Jan 11, 2021 |
| Technical Presentation (October 2018) | Technical | 44 slides | Oct 30, 2018 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (April 2017) | Investor day | 88 slides | Apr 27, 2017 |
| Innovations in Gastroenterology 2017 Symposium | Conference | 21 slides | Jan 4, 2017 |
| IPO Roadshow (November 2016) | IPO roadshow | 65 slides | Nov 1, 2016 |
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.04M | 6.53M | 61.8M | 85.8M | 64.4M | 6.29M | 8.36M | 4.01M | 101.0K | 3.00K |
| Cost of revenue | 3.19M | 3.46M | 33.3M | 49.4M | 36.9M | 2.26M | 2.84M | 2.13M | ||
| Gross profit | 4.85M | 3.07M | 28.5M | 36.4M | 27.5M | 4.03M | 5.52M | 1.88M | 101.0K | 3.00K |
| Research and development | 1.59M | 3.53M | 7.28M | 29.5M | 16.5M | 17.4M | 24.9M | 33.0M | 25.2M | 17.8M |
| Selling, general and administrative | 9.57M | 16.2M | 28.6M | 32.4M | 25.4M | 11.5M | 7.51M | 8.03M | 3.85M | 2.75M |
| Operating income | -14.6M | 12.6M | -42.8M | -81.1M | -63.7M | -43.2M | -39.3M | -52.0M | -30.5M | -22.0M |
| Depreciation and amortization | 588.0K | 1.45M | 2.14M | 1.91M | 1.71M | 997.0K | 90.0K | 81.0K | 44.0K | 36.0K |
| EBITDA | -14.0M | 14.1M | -40.7M | -79.2M | -62.0M | -42.2M | -39.2M | -51.9M | -30.5M | -22.0M |
| Interest expense | 2.06M | 9.61M | 42.4M | 16.7M | 12.8M | 438.0K | 167.0K | 77.0K | 375.0K | 212.0K |
| Net income | -8.27M | 23.9M | -71.7M | -97.7M | -76.2M | -42.3M | -38.8M | -45.5M | -29.4M | -21.1M |
| Earnings per share, basic | 0.00 | 0.01 | -0.12 | -0.21 | -0.21 | -0.14 | -0.17 | -0.26 | -0.23 | -0.19 |
| Earnings per share, diluted | 0.00 | 0.01 | -0.12 | -0.21 | -0.21 | -0.14 | -0.17 | -0.26 | -0.24 | -0.19 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.62M | 5.57M | 20.0M | 29.5M | 29.3M | 29.0M | 29.0M | 16.5M | 53.8M | 21.5M |
| Receivables | 2.54M | 2.59M | 34.5M | 31.7M | 28.7M | 1.22M | 958.0K | 1.53M | 99.0K | |
| Inventory | 3.65M | 4.39M | 11.0M | 14.8M | 6.53M | 1.88M | 769.0K | 653.0K | ||
| Current assets | 11.9M | 16.1M | 85.9M | 89.2M | 70.5M | 53.2M | 56.8M | 51.7M | 67.8M | |
| Property, plant and equipment | 135.0K | 193.0K | 502.0K | 572.0K | 511.0K | 228.0K | 163.0K | 230.0K | 165.0K | |
| Total assets | 18.0M | 23.0M | 158.9M | 181.2M | 180.2M | 74.1M | 62.4M | 57.3M | 74.2M | |
| Accounts payable | 1.17M | 3.28M | 4.23M | 11.7M | 11.6M | 4.18M | 3.32M | 4.80M | 60.0K | |
| Current liabilities | 22.2M | 20.0M | 197.5M | 81.5M | 73.2M | 10.6M | 10.4M | 11.8M | 5.36M | |
| Long-term debt | 83.6M | 81.4M | ||||||||
| Total debt | 83.6M | 81.4M | ||||||||
| Total liabilities | 22.7M | 21.0M | 207.3M | 172.3M | 166.4M | 14.1M | 11.2M | 12.3M | 11.5M | |
| Shareholders' equity | -4.68M | 2.07M | -48.4M | 8.88M | 13.9M | 60.0M | 51.2M | 45.1M | 62.7M | 60.1M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.37M | -35.8M | -29.2M | -65.0M | -48.6M | -40.7M | -34.5M | -44.8M | -28.3M | -17.8M |
| Capital spending | -9.00K | -11.0K | -198.0K | -115.0K | -406.0K | -168.0K | -23.0K | -146.0K | -85.0K | -14.0K |
| Free cash flow | -9.38M | -35.8M | -29.4M | -65.2M | -49.0M | -40.9M | -34.5M | -44.9M | -28.3M | -17.8M |
| Cash from investing | -9.00K | 4.00K | 8.30M | -8.14M | -35.6M | 5.16M | 5.35M | -18.6M | 24.5M | -21.2M |
| Cash from financing | 8.42M | 21.4M | 11.5M | 73.5M | 84.4M | 35.5M | 41.8M | 25.7M | 36.0M | 54.8M |
| Change in cash | -961.0K | -14.4M | -9.43M | 275.0K | 142.0K | -76.0K | 12.7M | -37.7M | 32.2M | 15.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 424B5 · Prospectus | Oct 13, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from RedHill Biopharma Ltd.’s releases
- Common shares
- 8,887,684
- Fully diluted
- 8,887,684
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 8,887,684 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,887,684 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Roni Mamluk Other companies: Ayala Pharmaceuticals Inc (President & CEO, Director · May 7, 2020 – Jan 19, 2023 · Past); Chiasma Inc (Director · Jul 15, 2015 – Aug 5, 2021 · Past) | Director · Since at least Mar 18, 2026 |
| Abe Schwartz | President and CEO of Schwartz Technologies Corporation · Since at least Nov 4, 2026 |
| Adi Frish | Chief Corporate & Business Development Officer · Since at least Dec 1, 2025 |
| Dror Ben-Asher | Chairman & CEO · Since at least Mar 18, 2026 |
| Gilead Raday | Chief Operating Officer · Since at least Mar 18, 2026 |
| Guy Goldberg | Chief Business Officer · Since at least Mar 18, 2026 |
| Ira Kalfus | Chief Medical Officer · Since at least Nov 4, 2026 |
| Kenneth Reed | Director · Since at least Nov 5, 2026 |
| Mark L. Levitt | Chief Scientific Officer · Since at least Oct 19, 2026 |
| Ofer Tsimchi | Director · Since at least Mar 18, 2026 |
All 15 people
| Person | Seat |
|---|---|
| Patricia Anderson | Senior VP Regulatory Affairs · Since at least Nov 5, 2026 |
| Razi Ingber | CFO · Since at least Mar 18, 2026 |
| Reza Fathi | Senior VP R&D · Since at least Nov 5, 2026 |
| Rick D. Scruggs | President, RedHill Biopharma Inc. & Chief Commercial Officer · Since at least Nov 4, 2026 |
| Shmuel Cabilly | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about RedHill Biopharma Ltd.